View Author
patient melanoma sentinel lymph cancer study survival interferon trial group stage treatment analysis tumour oncol peg-ifn -2 b number mitotic adjuvant observation mitotic rate tumor sample probe rt-pcr peg-ifn prognostic imaging injection table eortc cutaneous melanoma sentinel node biopsy biopsy signi result ulceration thickness lymphatic ann surg oncol pegylated blood sentinel node nodal injection site month image oncology activity concentration sentinel lymph nodes metastase cutaneou lymph nodes therapy metastasis-free survival detection factor melanoma cells information surgery sn tumour burden lymphoscintigraphy location thompson jf ficant disease radiation adjuvant therapy value procedure count phase tumor thickness metastasi american gamma journal density exposure
10 Most Recent Publications
|
Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection
(Article)
Ploeg, A.P.T. van der Akkooi, A.C.J. van Rutkowski, P. Cook, M. Nieweg, O.E. Rossi, C.R. Testori, A. Suciu, S. Verhoef, C. Eggermont, A.M.M. |
2012-10-01
|
|
Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion
(Article)
Testori, A. Verhoef, C. Kroon, H.M. Pennacchioli, E. Faries, M.B. Eggermont, A.M.M. Thompson, J.F. |
2011-09-01
|
|
Prognosis in patients with sentinel node - positive melanoma is accurately defined by the combined Rotterdam tumor load and dewar topography criteria
(Article)
Ploeg, A.P.T. van der Akkooi, A.C.J. van Van Leeuwen, P.A.M. Voit, C. Cataldo, F. Testori, A. Roberts, W.C. Hoekstra, H.J. Verhoef, C. Spatz, A. Eggermont, A.M.M. Rutkowski, P. Nowecki, Z.I. Michej, W. Mitra, A. Newton-Bishop, J.A. Cook, M. Nieweg, O.E. Van Den Hout, M.F.C.M. |
2011-06-01
|
|
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
(Article)
Eggermont, A.M.M. Bouwhuis, M.G. Kruit, W.H.J. Testori, A. Hagen, T.L.M. ten Yver, A. Xu, C. |
2010-03-01
|
|
Reply to F. Janku et al
(Article)
Eggermont, A.M.M. Bottomley, A. Suciu, S. Coens, C. Testori, A. Patel, P. Spatz, A. |
2010-01-10
|
|
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
(Article)
Fusi, A. Collette, S. Spatz, A. Eggermont, A.M.M. Keilholz, U. Busse, A. Suciu, S. Rietz, A. Santinami, M. Kruit, W.H.J. Testori, A. Punt, C.J.A. Dalgleish, A.G. |
2009-12-01
|
|
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma
(Article)
Chakera, A.H. Hesse, B. Even-Sapir, E. Eggermont, A.M.M. Gmeiner Stopar, T. Ingvar, C. Mihm Jr., M.C. McCarthy, S.W. Mozzillo, N. Nieweg, O.E. Scolyer, R.A. Starz, H. Burak, Z. Thompson, J.F. Trifirò, G. Viale, G. Vidal-Sicart, S. Uren, R. Waddington, W. Chiti, A. Spatz, A. Testori, A. Ballinger, J.L. Britten, A. Caracò, C. Cochran, A.J. Cook, M. Drzewiecki, K.T. Essner, R. |
2009-08-31
|
|
Utility of adjuvant systemic therapy in melanoma.
(Article)
Eggermont, A.M.M. Testori, A. Marsden, J. Hersey, P. Quirt, I. Petrella, T. Gogas, H. MacKie, R.M. Hauschild, A. |
2009-08-01
|
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
(Article)
Eggermont, A.M.M. Suciu, S. Kusic, Z. Dummer, R. Hauschild, A. Musat, E. Spatz, A. Keilholz, U. Santinami, M. Testori, A. Kruit, W.H.J. Marsden, J. Punt, C.J.A. Salès, F. Gore, M. MacKie, R.M. |
2008-07-14
|
|
Long-term protective effect of mature DC-LAMP
+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
(Article)
Elliott, B. Scolyer, R.A. Testori, A. Eggermont, A.M.M. MacKie, R.M. Robert, C. Cook, M. Thompson, J.F. Angevin, E. Spatz, A. Suciu, S. Lebecque, S. Rimoldi, D. Gugerli, O. Musat, E. Sharma, R.N. Lienard, D. Keilholz, U. |
2007-07-01
|
